12:00 AM
 | 
Dec 24, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Oritavancin: Phase III data

In patients with microbiologically-confirmed methicillin-resistant Staphylococcus aureus (MRSA) infection (n=204), 80.8% of patients receiving oritavancin achieved an early clinical response vs. 80% for vancomycin. Additionally, the proportion of patients in the subgroup with a >20% reduction in lesion area at 48-72 hours was 90.4% in the oritavancin arm vs. 84% in the vancomycin arm. Furthermore, 82.7% of patients in the oritavancin arm achieved investigator-assessed clinical cure vs. 83% for vancomycin. The proportion of patients who experienced >=1 adverse event was...

Read the full 376 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >